First Hawaiian Bank’s BioCryst Pharmaceuticals BCRX Stock Holding History

First Hawaiian Bank’s Portfolio BCRX Stock Details BCRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-51,735	Closed	-$841K	–	889
2022 Q1	$841K	Buy	51,735 +20,970	+68%	+$336K	0.03%	437
2021 Q4	$426K	Hold	30,765	–	–	0.01%	679
2021 Q3	$442K	Sell	30,765 -10,745	-26%	-$169K	0.02%	557
2021 Q2	$656K	Sell	41,510 -3,110	-7%	-$42.3K	0.03%	411
2021 Q1	$454K	Sell	44,620 -17,660	-28%	-$182K	0.02%	567
2020 Q4	$464K	Sell	62,280 -2,810	-4%	-$14.5K	0.02%	515
2020 Q3	$224K	Buy	+65,090	New	+$279K	0.01%	692

Other funds holding BCRX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

PAMS

Pictet Asset Management (Switzerland) Geneva 73, Switzerland $84.3B AUM 26.5% 1-Year Est. Return

Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

First Hawaiian Bank's BCRX Position: Q2 2022 in Review

First Hawaiian Bank sold out of BioCryst Pharmaceuticals (BCRX) in Q2 2022, closing a stake of 51,735 shares — an estimated $841K sold.

First Hawaiian Bank first reported a position in BCRX in Q3 2020 and held it in 7 quarters. The position peaked at $841K in Q1 2022. 221 funds tracked by Wall St. Rank hold BCRX as of Q2 2022.

First Hawaiian Bank reported no remaining BioCryst Pharmaceuticals position as of Q2 2022 after selling out during the quarter.
First Hawaiian Bank sold 51,735 BioCryst Pharmaceuticals shares in Q2 2022, an estimated $841K.
First Hawaiian Bank first reported a position in BioCryst Pharmaceuticals in Q3 2020 and held it in 7 quarters.
First Hawaiian Bank's BioCryst Pharmaceuticals position peaked at $841K in Q1 2022.
221 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q2 2022.

Based on First Hawaiian Bank's 13F filing for Q2 2022, filed 22 Jul 2022.